| Disease | THERE WERE SOME SPECTACULAR INDIVUAL RESPONSES IN BOTH GROUPS, BUT NO STATISTICALLY SIGNIFICANT DIFFERENCES, AND NO DIFFERENCES IN SIDE-EFFECTS.
QUESTIONNAIRE WAS RECORDED AT-1,0,1,3,6,9 AND 12 WEEKS, AND A NON-BLIND FOLLOW-UP FOR A FURTHER 6-WEEKS ON GINKGO. HAMILTON ANXIETY AND DEPRESSION RATINGS WERE MADE AT 0,6 AND 12 WEEKS AND SIMPLE GLOBAL ASSESSMENTS OF ALERTNESS AND MEMORY.
EFFICACY ANALYSIS WAS CARRIED OUT ON 8 MALES AND 5 FEMALES ON PLACEBO AND 6 MALES AND 5 FEMALES ON GINKGO, COMPLETING THE FULL 12 WEEKS TREATMENT. NOT INCLUDED WERE THREE SUBJECTS WHO DROPPED OUT AFTER 6 WEEKS. A VALIDATED, SEX GENDER-ORIENTATED
A TRIPLE-BLIND (INVESTIGATOR,PATIENT,STATISTICIAN), RANDOMIZED, PLACEBO-CONTROLLED, TRIAL OF GINKGO BILOBA 240 MG DAILY WAS CARRIED OUT. FOLLOWING A 1 WEEK CONTROL, IT WAS GIVEN TO 24 PATIENTS WITH SEXUAL IMPAIRMENT DUE TO ANTIDEPRESSANT DRUGS. |